Therapeutic Approach

Archive: March, 2017

Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial

Los Angeles, California, March 28, 2017 – Ritter Pharmaceuticals, Inc. (the “Company”) today announced topline findings from its Phase 2b/3 study designed to evaluate RP-G28 in subjects with lactose intolerance. Results from the 377-subject trial show a clinically meaningful benefit to subjects in the reduction of lactose intolerance symptoms across a variety of outcome measures. The […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD